Literature DB >> 1107123

Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insluin secretion.

J M Feldman, B Chapman.   

Abstract

Using an in vitro rabbit pancreas system, we studied the effect of monoamine oxidase (MAO) inhibitors on flucose-stimulated insulin secretion. We evaluated the effect of both brief (15 min) and prolonged (60 min) exposure of pancreas segments to non-hydrazine (harmine, alpha-methyltryptamine, tranylcypromine and pargyline) and hydrazine (phenelzine, nialamide, iproniazid) type MAO inhibitors. All of the hydrazine type MAO inhibitors potentiated glucose-stimulated insulin secretion. Of the non-hydrazine inhibitors, only harmine and alpha-methyltryptamine potentiated glucose-stimulated insulin secretion. Hydrazine, although not itself an MAO inhibitor, also potentiated insulin secretion. Sixty minutes of exposure to tranylcypromine or alpha-methyltryptamine caused a decrease in insulin secretion. These MAO inhibitors are primary amines and primary amines can inhibit insulin secretion. The dopamine (DA) or serotonin (5-HT) content of the B-cells was increased by incubating rabbit pancreas with L-3, 4-dihydroxyphenylalanine (L-Dopa) or 5-hydroxytryptophan (5-HTP) for forty-five minutes prior to stimulation with glucose. Non-hydrazine MAO inhibitors increased dopamine inhibition of insulin secretion and either did not alter, or decreased serotonin inhibition of insulin secretion. Rabbit pancreatic islets were isolated using the collagenase digestion technique. The MAO activity of islet homogenates was determined using 5-HT and DA as substrates. Rabbit islet MAO has only one-tenth the specific activity against 5-HT (35 +/- 8.7 mumumoles/mg/min, M +/- SEM) that it has against DA (357 +/- 62.3 mumumoles/mg/min). This suggests that one reason that MAT inhibitors do not increase serotonin inhibition of insulin secretion is because MAO is not the major pathway for 5-HT inactivation in rabbit pancreatic islets. These studies suggest that MAO inhibitors alter insulin secretion, by both decreasing B-cell monoamine degradation and by mechanisms that do not involve MAO inhibition.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1107123     DOI: 10.1007/bf01222097

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  32 in total

1.  Amine oxidase and amine metabolism.

Authors:  H BLASCHKO
Journal:  Pharmacol Rev       Date:  1952-12       Impact factor: 25.468

2.  Relation of oxygen and temperature in the preservation of tissues by refrigeration.

Authors:  J H HANKS; R E WALLACE
Journal:  Proc Soc Exp Biol Med       Date:  1949-06

3.  Mechanisms of catecholamine inactivation by the endocrine pancreas.

Authors:  J M Feldman; B Chapman
Journal:  Diabetes       Date:  1974-09       Impact factor: 9.461

4.  Amino acid conversion into 5-hydroxytryptamine in pancreatic beta-cells.

Authors:  E Gylfe; B Hellman; J Sehlin; I B Taljedal
Journal:  Endocrinology       Date:  1973-10       Impact factor: 4.736

5.  Potentiation of insulin secretion in vitro by serotonin antagonists.

Authors:  J M Feldman; K E Quickel; H E Lebovitz
Journal:  Diabetes       Date:  1972-07       Impact factor: 9.461

6.  Pancreatic biogenic amines and insulin secretion in health and disease.

Authors:  H E Lebovitz; J M Feldman
Journal:  Fed Proc       Date:  1973-07

7.  The occurrence of biogenic monoamines in the mammalian endocrine pancreas.

Authors:  L Cegrell
Journal:  Acta Physiol Scand Suppl       Date:  1968

8.  Stimulatory effect of nialamide on serum levels on insulin.

Authors:  J J Gagliardino; R E Hernandez; R R Rodriguez; H C Lauri
Journal:  Am J Physiol       Date:  1970-08

9.  Possible role of hydrazine group in hypoglycemia associated with the use of certain monoamine-oxidase inhibitors (MAOI's).

Authors:  W Z Potter; D S Zaharko; L V Beck
Journal:  Diabetes       Date:  1969-08       Impact factor: 9.461

10.  Amine oxidase. XIV. Isolation and characterization of the multiple beef liver amine oxidase components.

Authors:  B Gomes; I Igaue; H G Kloepper; K T Yasunobu
Journal:  Arch Biochem Biophys       Date:  1969-06       Impact factor: 4.013

View more
  6 in total

1.  Brain-penetrant LSD1 inhibitors can block memory consolidation.

Authors:  Ramesh Neelamegam; Emily L Ricq; Melissa Malvaez; Debasis Patnaik; Stephanie Norton; Stephen M Carlin; Ian T Hill; Marcelo A Wood; Stephen J Haggarty; Jacob M Hooker
Journal:  ACS Chem Neurosci       Date:  2011-10-18       Impact factor: 4.418

2.  Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.

Authors:  S Lenzen; H Nahrstedt; U Panten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

3.  Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.

Authors:  Anthony Raffo; Kolbe Hancock; Teresa Polito; Yuli Xie; Gordon Andan; Piotr Witkowski; Mark Hardy; Pasquale Barba; Caterina Ferrara; Antonella Maffei; Matthew Freeby; Robin Goland; Rudolph L Leibel; Ian R Sweet; Paul E Harris
Journal:  J Endocrinol       Date:  2008-07       Impact factor: 4.286

4.  Localization of monoamine oxidase A and B and semicarbazide-sensitive amine oxidase in human peripheral tissues.

Authors:  D Ramonet; M Rodríguez; J Saura; J M Lizcano; M Romera; M Unzeta; C Finch; E Billett; N Mahy
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

5.  Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report.

Authors:  Fawzi A Bachet Ibrahim; Fauzia Rashid; Azza A Bin Hussain; Fatheya Alawadi; A Bashier
Journal:  J Med Case Rep       Date:  2017-02-02

6.  Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice.

Authors:  Christian Carpéné; Saioa Gómez-Zorita; Alice Chaplin; Josep Mercader
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.